AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Oramed Pharmaceuticals Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SK4M90
4.13▲ 0.01 (0.24%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
4.12
Day's Range
4.06 – 4.17
52-Week Range
2.09 – 5.47
Volume
115.7K
Avg Volume
158.2K
Share Statistics
Shares Outstanding
Employees
13
Exchange
XNAS
Listed
2004-04-19
Share count as of August 10, 2026

Oramed Pharmaceuticals Inc. (ORMP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Oramed Pharmaceuticals Inc. (ORMP)
What is Oramed Pharmaceuticals Inc.'s Market Cap?
Oramed Pharmaceuticals Inc.'s Market Cap is $171.8M, based on as-reported figures from SEC (XBRL) filings.
What is Oramed Pharmaceuticals Inc.'s Trailing P/E?
Oramed Pharmaceuticals Inc.'s Trailing P/E is 1.6×, based on as-reported figures from SEC (XBRL) filings.
What is Oramed Pharmaceuticals Inc.'s Revenue (TTM)?
Oramed Pharmaceuticals Inc.'s Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Oramed Pharmaceuticals Inc.'s Net Income (TTM)?
Oramed Pharmaceuticals Inc.'s Net Income (TTM) is $110.0M, based on as-reported figures from SEC (XBRL) filings.
What is Oramed Pharmaceuticals Inc.'s EBITDA?
Oramed Pharmaceuticals Inc.'s EBITDA is -$14.1M, based on as-reported figures from SEC (XBRL) filings.
What is Oramed Pharmaceuticals Inc.'s Diluted EPS (TTM)?
Oramed Pharmaceuticals Inc.'s Diluted EPS (TTM) is 2.64, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ORMPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
REVENUES——
YoY growth————
COST OF REVENUE——
GROSS PROFIT——
% of revenue————
RESEARCH AND DEVELOPMENT EXPENSES
GENERAL AND ADMINISTRATIVE EXPENSES
OPERATING LOSS
% of revenue————
OTHER INCOME, NET
FINANCIAL INCOME, NET
INCOME BEFORE TAX EXPENSES
TAX BENEFIT (EXPENSES)
NET INCOME—
% of revenue————
NET INCOME (LOSS) ATTRIBUTABLE TO:
NON-CONTROLLING INTERESTS——
COMPANY’S STOCKHOLDERS
% of revenue————
BASIC INCOME PER SHARE OF COMMON STOCK
DILUTED INCOME PER SHARE OF COMMON STOCK